Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent

C1348

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).

2018-04-02

2021-12-31

2026-03-31

Active (not recruiting)

Early phase I

3008

Inclusion Criteria: * Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent under the setting of acute coronary syndrome * Patients who are capable of oral dual antiplatelet therapy consisting of aspirin and P2Y12 receptor antagonist Exclusion Criteria: * Patients requiring oral anticoagulants * Patients with medical history of intracranial hemorrhage * Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention * Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents implanted at the time of enrollment * Patients confirmed to have no tolerability to clopidogrel before enrollment * Patients requiring continuous administration of antiplatelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 3008, 'type': 'ACTUAL'}}

2023-04-04